Cumulus’ gamified dry EEG system tops lab monitoring in trial
An at-home electroencephalogram (EEG) headset used alongside game-like cognitive tasks developed by UK company Cumulus Neuroscience has been shown to be more effective than lab-based […]
neurology
Koneksa aims to answer Parkinson’s-tracking challenge with AI
Healthcare technology firm Koneksa will carry out a study to evaluate whether digital biomarkers can be used to track the progression of Parkinson’s disease – […]
Biogen gets much-needed pipeline lift with speedy ALS drug review
Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy […]
Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s
Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s disease candidate KW-6356, a drug in the […]
Memory Health CEO shares approach to combating Alzheimer’s disease
Memory Health CEO Edward Shehab talked about taking a preventive approach to neurodegenerative conditions.
AbbVie cuts Alzheimer’s alliance with Alector in half
AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer’s disease candidate AL003, which aims to tackle the neurodegenerative disease by […]
Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan
The FDA has started an accelerated review of Eisai and Biogen’s a new amyloid-targeting antibody lecanemab for Alzheimer’s disease, with a 6 January deadline that […]
Biogen waves bye to $217m ALS partnership with Karyopharm
Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been […]
Amylyx bags first approval for ALS drug Albrioza
Amylyx Pharmaceuticals’ efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run into some roadblocks, so an approval by […]
Biogen bolsters pipeline again with Alectos deal
Biogen has added a preclinical-stage drug candidate for Parkinson’s disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a […]
Cumulus puts its digital biomarkers for CNS diseases to the test
Cumulus Neuroscience has started a pair of clinical trials to gauge the value of a panel of physiological and digital biomarkers in tracking the course […]
AbbVie files continuous Parkinson’s therapy ABBV-951 in US
AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current […]
Recent advances in neurological disorders
Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. What may be important […]
Biogen grabs MS music therapy from MedRhythms in $120m deal
Biogen has licensed rights to a digital therapeutic (DTx) developed by MedRhythms which combines sensors, software, and music to help people with multiple sclerosis tackle […]
FDA approves first in vitro test for early Alzheimer’s disease
The US FDA has authorised a new test that can detect amyloid plaques in early-stage Alzheimer’s disease without the use of PET scans, which expose […]
Biogen pulls EU application for Alzheimer’s drug Aduhelm
Biogen has given up on seeking approval for its Alzheimer’s disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it […]
PreciseDx AI diagnostic can detect early-stage Parkinson’s
Diagnosing Parkinson’s in the earliest stages before symptoms become serious is a major challenge in medicine, and digital health company PreciseDx thinks it may have […]
BioArctic left in the cold as AbbVie abandons Parkinson’s pact
One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – […]
Oligonucleotide Therapeutics and Delivery Conference
Oligonucleotide Therapeutics and Delivery Conference 2022 Date: 21st – 22nd September 2022 Location: London, UK Website: www.oligonucleotide.co.uk/pharmaphorum Advancements in extra-hepatic delivery of oligonucleotides The Oligonucleotide […]
NICE backs Biogen’s Vumerity for multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s oral therapy Vumerity, after NICE recommended the […]
Gaming health firm GripAble raises $11m for rehab platform
GripAble has raised $11 million in first-round financing that will be used to advance its digital health approach to rehabilitation for people with neurological and […]
Study uncovers new Alzheimer’s genes, links to immune disruption
The largest-ever study of genetics in Alzheimer’s disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder. The new […]
Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug
By a narrow margin, an FDA advisory committee has voted against approval of Amylyx’ experimental medicine for amyotrophic lateral sclerosis until the company can provide […]
Biogen finally publishes its phase 3 Aduhelm data
After months of debate about the validity of its phase 3 clinical trials for Alzheimer’s therapy Aduhelm, Biogen has published the results in a peer-review […]
Eisai hands off responsibility for Aduhelm to Biogen
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US […]
Roche starts new four-year trial of Alzheimer’s drug gantenerumab
With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the […]
AbbVie adds to neuroscience pipeline with $1bn Syndesi buy
Four years after spinning out from Belgium’s UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The […]
MindMaze raises $105m to seek out new neurological DTx
Swiss digital health company MindMaze has raised $105 million to help take its digital therapeutics (DTx) for neurological diseases like stroke onto the global stage, […]
MindMaze fuels growth in gamified neurorehab with $105M in financing
The financing round was led by Concord Health Partners, with AlbaCore Capital Group and Hambro Perks also contributing. The latest haul follows a $125 million […]
BREAKING: MindMaze Lands Fresh $105M for Digital Neuro-Therapeutics
By JESSICA DaMASSA, WTF HEALTH You may know the term “digital therapeutics,” but how about the specialized category of “digital neuro-therapeutics”? MindMaze, which has developed […]
Eisai bites back against restricted coverage plan for Aduhelm
Japanese drugmaker Eisai has published comments filed with the US Centers for Medicare & Medicaid Services over its restrictive coverage proposal for beleaguered Alzheimer’s drug […]
Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision
Eli Lilly has backed away from plans to file Alzheimer’s drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement […]
Biogen tweaks confirmatory trial of Alzheimer’s drug Aduhelm
Biogen and Eisai have increased the earning potential of their Alzheimer’s drug Aduhelm by expanding the post-marketing trial of the drug required by the FDA […]
Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA
Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s programmes, as the FDA awards a fast-track […]
Biogen takes axe to Aduhelm price in a bid to drive take-up
Biogen has cut the list price of its Alzheimer’s disease therapy in half from $56,000 to $28,200 a year, before the outcome of an ongoing […]
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted […]
Viagra ‘should be tested as Alzheimer’s therapy’
Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a lower risk of developing Alzheimer’s disease – […]
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal
Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – […]
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone. Now, it’s ready […]
CHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogen
Biogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s drug Aduhelm when it comes up for […]
AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial
AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving […]
Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trial
Eli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab, and is planning to take on Biogen […]
UK hospital will use MindMaze game to aid stroke recovery
A hospital trust has become the first in the UK to deploy a gaming system developed by Swiss company MindMaze that is intended to help […]
SOM’s AI-discovered drug shows promise in Huntington’s disease
A drug originally developed for high blood pressure could find a new use in the treatment of Huntington’s disease, thanks to an artificial intelligence-based drug […]
Could Pfizer’s Inlyta have a role in Alzheimer’s disease?
Pfizer’s tyrosine kinase inhibitor Inlyta is already a cornerstone of treatment for some forms of cancer, but could have potential as a therapy for Alzheimer’s […]
Biogen, Eisai double down on Alzheimer’s with lecanemab filing
Biogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but the partners are forging ahead with their […]
It’s time to do better for patients with rare neurological disorders
Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare […]
Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research
Danish drugmaker Lundbeck has teamed up with Inscopix – the developer of a technology that can film neurons in the brain in real time – […]
Amylyx preps filing for its ALS drug after FDA feedback
Just a few months ago, Amylyx was talking about having to complete another clinical trial before it could file for FDA approval of its drug […]
First subject dosed in psilocybin trial for rare headache disorder
The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), […]
Startup Neuroglee raises $10m for virtual neurology clinics
A digital health company focusing on neurodegenerative disorders – Neuroglee Therapeutics – has raised $10 million in first-round funding to roll out a virtual neurology […]
Server cans autism hope bumetanide after phase 3 fails
Servier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to market for people with autism spectrum disorder […]
AC Immune claims half a win for tau drug in Alzheimer’s trial
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one of its objectives in a phase 2 […]
Beckley Psytech raises $80m for psychedelic meds development
UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical […]
Morning Distort
By MARTIN A. SAMUELS A 35 year old woman complains of weakness of the right side of her face and pain behind the right ear. […]
Lilly sets out its stall on donanemab as filing approaches
The FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
Biogen bites back at critics of Aduhelm after drug’s slow start
Biogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting the company to issue a rebuke to […]
Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readout
Phase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of last year, but the company is already […]
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson’s disease which is currently […]
Ipsen tries again in Parkinson’s disease with $363m IRLAB deal
French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for […]
FDA staffers defend Aduhelm approval in JAMA editorial
Three FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm have defended their actions, arguing that […]
How’s my driving? GPS tracking spots Alzheimer’s with 86% accuracy
Diagnosing Alzheimer’s disease is still a challenge, particularly in its earliest stages, but a new study suggests that subtle changes in behaviour whilst driving could […]
Biogen builds MS pipeline via $125m deal with China’s InnoCare
Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese biotech InnoCare currently in mid-stage clinical testing. […]
US starts review of Aduhelm coverage amid fears of Medicare hit
The US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm will be covered by Medicare, to see […]
FDA whittles back Aduhelm approval amid concern over broad label
One of the criticisms levelled at the FDA over its approval of Biogen and Eisai’s Alzheimer’s disease drug Aduhelm was its decision to clear use […]
ICER revises its view of Aduhelm’s price – but not by much
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on […]
ICER revises its view of Aduhelm’s price – but not by much
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on […]
Biogen abandons tau antibody for Alzheimer’s after phase 2 miss
Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been […]
Consumer group seeks resignation of top FDA staffers over Aduhelm okay
With the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy […]
And then there were three: another FDA adcomm member quits over Aduhelm
The fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning […]
Double resignation over Aduhelm approval depletes FDA’s CNS adcomm
Two members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s disease drug Aduhelm despite an overwhelming vote […]
Aduhelm approval could signal new era for CNS drugs; analysts
The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the […]
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinic
Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish […]
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag
The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. […]
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab
Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab as the first-ever disease-modifying treatment for Alzheimer’s […]
Akili raises $110m to build its digital therapeutics pipeline
Digital health player Akili has raised $110 million fourth-round funding, backed by a number of pharma groups, as it works towards extending its product range […]
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and […]
Exscientia starts trials of AI-designed Alzheimer’s drug
Exscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based […]
CHMP backs Roche’s Enspryng for rare nerve disease NMOSD
Roche’s Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending the treatment options for people with the […]
Safety study pushes back phase 3 trial of Newron’s schizophrenia drug
Switzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to complete a small study to show safety […]
FDA grew too close to Biogen during Alzheimer’s drug development, doctors say
The FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its own expert advisers who are urging the […]
Roche stops dosing in trial of Huntington’s disease hopeful tominersen
Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed with Ionis, after a pre-planned review by […]
COVID-19 increased demands on carers’ wellbeing, study finds
COVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, according to a global study. Embracing Carers […]
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems
Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs. Ipsen’s John Chaddock […]
Early data back J&J and AC Immune’s Alzheimer’s jab
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a […]
BMS’ MS pill gets funding in Scotland after rejection in England by NICE
Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide following a draft rejection in England by […]
Competition for Neurocrine as Gocovri picks up new Parkinson’s indication
Adamas Pharmaceuticals’ Parkinson’s drug Gocovri has a new indication as an adjunctive treatment for levodopa/carbodopa in patients with Parkinson’s disease experiencing ‘off’ episodes. The new […]
Biogen shares soar as FDA delays decision on aducanumab
The FDA has delayed its decision on aducanumab, the troubled Alzheimer’s drug from Biogen and Eisai by three months, raising hopes that it could be […]
Stress not a significant factor in migraine attacks, study finds
New findings from a digital study have challenged the belief that stress is a significant factor in triggering migraine attacks. Results came from a study […]
UCB backs epilepsy-focused digital heath startup Nile AI
Belgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing new projects. One of those is now […]
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?
When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although […]
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-ups
US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop […]
Neurology’s Growing Need for Disposable Technologies
By Boris Goldstein, Co-Founder & Executive Chairman at Brain Scientific COVID-19 is known for its impacts on a patient’s respiratory system, but it has also […]
Angelini and Arvelle create neurology player with $960m merger
There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth […]
Clene goes public with gold-based neurology nanotechnology
Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseases including Parkinson’s disease. Over […]
AI-designed serotonin tracker could help develop neurology drugs
A serotonin sensor designed using Artificial Intelligence (AI) could help scientists study sleep and mental health and potentially find new neurology drugs. The US National […]
Novartis buys neurology biotech Cadent for up to $770m
Novartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The big Swiss pharma already has a presence […]
9th Annual Neurodegenerative Drug Development Summit
The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative […]
Lilly pays up to $1.04bn for neurology gene therapy biotech Prevail
Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a deal potentially worth more than $1 billion. […]
Swiss start-up Noema raises $59m to develop neurology drugs offloaded by Roche
Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche. The company is developing four […]
Eisai forges CNS alliance with UK’s Wren Therapeutics
Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus […]
Biogen bulks up pipeline with Sage drugs in $3bn deal
With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 […]
FDA panel unimpressed with data for Alzheimer’s drug aducanumab
The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for […]
China’s Green Valley prepares US trial of Alzheimer’s drug inspired by algae
As an influential panel of FDA-appointed experts prepares its verdict on Biogen’s Alzheimer’s drug, a little known China-based pharma is hoping to succeed where big […]
Novartis’ Aimovig tops topiramate in migraine face-off
Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine […]
Salvia’s migraine implant could be breakthrough, says FDA
An implantable neurostimulation migraine device from Salvia BioElectronics has gained Breakthrough Device Designation from the FDA. Traditional neurostimulation systems are not designed to be compatible […]
NICE changes its mind on Novartis’ progressive MS drug Mayzent
UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance. The […]
Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism
Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a […]
Recent Advances in Alzheimer’s Disease Prevention
Recent Advances in Alzheimer’s Disease Prevention A prominent neurologist reviews what is known (and not known) about recent evidence-based advances in Alzheimer’s Disease prevention. The […]
Patient from the USA Underwent Spinal Discectomy Surgery in Turkey
Mr. James Evans suffered from serious back pain and he was taking pain injections to ease his pain. After the prolonged use of pain injections, […]
Mission successful for Novartis after FDA approves ofatumumab in MS
It’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the former cancer drug has been repurposed. The […]
Roche takes on Alexion as FDA approves satralizumab in NMOSD
The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the brand name Enspryng. Roche is taking on […]
MdDS Makes You Feel Like You’re Still on the Boat
MdDS Makes You Feel Like You’re Still on the Boat MdDS is an under recognized neurologic disorder where the rocking sensation you experience after getting […]
Bayer adds menopause drug to pipeline with KaNDy acquisition
Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline. […]
Roche takes on pricey rivals as FDA approves SMA drug
Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is the third […]
Biogen signs $2.1 billion Parkinson’s disease deal with Denali
Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion. […]
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m
Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up […]
Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease
Shots: The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without), b) 699 in Sweden (301 […]
Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease
Shots: UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of […]
FDA approves Jazz Pharmaceuticals’ narcolepsy therapy
The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, offering a regime with less sodium than […]
Pandemic and currency headwinds hurt Roche in first half
Roche has announced half-year results showing the COVID-19 pandemic affected sales of its key products, with currency headwinds also weighing on revenues. The Swiss pharma’s […]
